Loading...
Alemtuzumab by Continuous Intravenous Infusion Followed by Subcutaneous Injection Plus Rituximab in the Treatment of Patients With Chronic Lymphocytic Leukemia Recurrence
BACKGROUND: Monoclonal antibodies may be used more effectively in combination. A previous study of intravenous (iv) bolus alemtuzumab plus rituximab in patients with chronic lymphocytic leukemia (CLL) recurrence produced a response rate of 54% after a 4-week treatment period. METHODS: To optimize do...
Na minha lista:
| Udgivet i: | Cancer |
|---|---|
| Main Authors: | , , , , , |
| Format: | Artigo |
| Sprog: | Inglês |
| Udgivet: |
2010
|
| Fag: | |
| Online adgang: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4476388/ https://ncbi.nlm.nih.gov/pubmed/20225334 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/cncr.24958 |
| Tags: |
Tilføj Tag
Ingen Tags, Vær først til at tagge denne postø!
|